BACKGROUND: Complete axillary lymph node dissection (ALND) after a positive sentinel lymph node biopsy (SLNB) remains the standard practice. As nodal surgery has long been considered a staging procedure without a clear survival benefit, the need for ALND in all patients is debatable. The purpose of this study was to examine differences in survival for patients undergoing SLNB alone versus SLNB with complete ALND. METHODS: Patients with breast cancer who underwent SLNB and were found to have nodal metastases were identified from the Surveillance, Epidemiology, and End Results database (1998-2004). Clinicopathologic and outcomes data were examined for patients who underwent SLNB alone versus SLNB with ALND. RESULTS: We identified 26,986 patients with disease-positive lymph nodes; 4,425 (16.4%) underwent SLNB alone, and 22,561 (83.6%) underwent SLNB with ALND. Patients were significantly more likely to undergo SLNB alone if they were older (median 59 years old) or if the tumor was low grade and estrogen receptor positive. From 1998 to 2004, the proportion of patients with micrometastasis in the sentinel lymph nodes who underwent SLNB alone increased from 21.0 to 37.8% (P < 0.001). At a median follow-up of 50 months, there were no statistically significant differences in overall survival (OS) between patients who underwent SLNB alone versus complete ALND. CONCLUSIONS: There is an increasing trend toward omitting ALND in patients with micrometastatic nodal disease identified by SLNB. Compared with SLNB alone, completion ALND does not seem to be associated with improved survival for breast cancer patients with micrometastasis in the sentinel lymph nodes.
BACKGROUND: Complete axillary lymph node dissection (ALND) after a positive sentinel lymph node biopsy (SLNB) remains the standard practice. As nodal surgery has long been considered a staging procedure without a clear survival benefit, the need for ALND in all patients is debatable. The purpose of this study was to examine differences in survival for patients undergoing SLNB alone versus SLNB with complete ALND. METHODS:Patients with breast cancer who underwent SLNB and were found to have nodal metastases were identified from the Surveillance, Epidemiology, and End Results database (1998-2004). Clinicopathologic and outcomes data were examined for patients who underwent SLNB alone versus SLNB with ALND. RESULTS: We identified 26,986 patients with disease-positive lymph nodes; 4,425 (16.4%) underwent SLNB alone, and 22,561 (83.6%) underwent SLNB with ALND. Patients were significantly more likely to undergo SLNB alone if they were older (median 59 years old) or if the tumor was low grade and estrogen receptor positive. From 1998 to 2004, the proportion of patients with micrometastasis in the sentinel lymph nodes who underwent SLNB alone increased from 21.0 to 37.8% (P < 0.001). At a median follow-up of 50 months, there were no statistically significant differences in overall survival (OS) between patients who underwent SLNB alone versus complete ALND. CONCLUSIONS: There is an increasing trend toward omitting ALND in patients with micrometastatic nodal disease identified by SLNB. Compared with SLNB alone, completion ALND does not seem to be associated with improved survival for breast cancerpatients with micrometastasis in the sentinel lymph nodes.
Authors: G Cserni; D Gregori; F Merletti; A Sapino; M P Mano; A Ponti; S Sandrucci; B Baltás; G Bussolati Journal: Br J Surg Date: 2004-10 Impact factor: 6.939
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: K M McMasters; A E Giuliano; M I Ross; D S Reintgen; K K Hunt; D R Byrd; V S Klimberg; P W Whitworth; L C Tafra; M J Edwards Journal: N Engl J Med Date: 1998-10-01 Impact factor: 91.245
Authors: Jacqueline Sara Jeruss; David J Winchester; Stephen F Sener; Erika M Brinkmann; Malcolm M Bilimoria; Ermilo Barrera; Eihab Alwawi; Angel Nickolov; G M Schermerhorn; David J Winchester Journal: Ann Surg Oncol Date: 2004-12-27 Impact factor: 5.344
Authors: Arpana M Naik; Jane Fey; Mary Gemignani; Alexandra Heerdt; Leslie Montgomery; Jeanne Petrek; Elisa Port; Virgilio Sacchini; Lisa Sclafani; Kimberly VanZee; Raquel Wagman; Patrick I Borgen; Hiram S Cody Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: Elizabeth A Mittendorf; Kelly K Hunt; Judy C Boughey; Roland Bassett; Amy C Degnim; Robyn Harrell; Min Yi; Funda Meric-Bernstam; Merrick I Ross; Gildy V Babiera; Henry M Kuerer; Rosa F Hwang Journal: Ann Surg Date: 2012-01 Impact factor: 12.969
Authors: M Hubalek; R Bartsch; M Gnant; K S Kapp; A Lang; S Lax; P Lukas; W Neunteufel; G Pristauz; R Reitsamer; P Sandbichler; P Schrenk; C Singer; K Tamussino; J Tschmelitsch; A G Zeimet; C Marth Journal: Geburtshilfe Frauenheilkd Date: 2012-04 Impact factor: 2.915
Authors: Catherine E Loveland-Jones; Karen Ruth; Elin R Sigurdson; Brian L Egleston; Marcia Boraas; Richard J Bleicher Journal: Breast Cancer Res Treat Date: 2014-01-19 Impact factor: 4.872
Authors: Abigail S Caudle; Kelly K Hunt; Susan L Tucker; Karen Hoffman; Sarah M Gainer; Anthony Lucci; Henry M Kuerer; Funda Meric-Bernstam; Ruchita Shah; Gildy V Babiera; Aysegul A Sahin; Elizabeth A Mittendorf Journal: Ann Surg Oncol Date: 2012-07-31 Impact factor: 5.344